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Paracoccidioidomycosis (PCM) is a granulomatous disease caused by the dimorphic fungus Paracoccidioides
brasiliensis. The immunoglobulin classes and isotypes of antibodies directed to acidic glycosphingolipids
(GSLs) and glucosylceramide of P. brasiliensis were determined by enzyme-linked immunosorbent assay of sera
from 31 PCM patients. The reactivities of 38 serum samples were analyzed by considering the stage of
treatment: before antifungal treatment (n  10), during 1 to 4 months of treatment (T1-4; n  9), during 5 to
12 months of treatment (T5-12; n  9), and posttreatment (PT; n  10). Sera from healthy subjects (n  12)
were used as controls. Only the GSL Pb-1 antigen, which presents the carbohydrate structure Galf1-
6(Man1-3)Man1, was reactive with the PCM patient sera. The PCM patient sera did not react with Pb-2,
which lacks the Galf residue and which is considered the biosynthetic precursor of Pb-1, indicating that the
Galf residue is essential for antibody reactivity. The Pb-1 glycolipid from nontreated patients elicited a primary
immune response with immunoglobulin M (IgM) production and subsequent switching to IgG1 production.
The IgG1 titer increased after the start of antifungal treatment (T1-4 group), and general decreases in the
anti-Pb-1 antibody titers were observed after 5 months of treatment (T5-12 and PT groups). The Pb-1 antigen,
an acidic GSL with terminal Galf residue, has potential application as an elicitor of the host immune response
in patients with PCM.
Paracoccidioidomycosis (PCM) is a systemic granulomatous
fungal disease caused by the thermally dimorphic fungus Para-
coccidioides brasiliensis, which grows in the yeast form at 36°C
and in the mycelium form at 23°C.
P. brasiliensis infection is endemic in most countries of South
and Central America, particularly Brazil, Argentina, Colom-
bia, and Venezuela (3). It is estimated that as many as 10
million people in areas where PCM is endemic, mostly farm
workers, may be infected by inhalation of P. brasiliensis micro-
conidia from the soil, which is suspected to be the natural
habitat of this fungus (3, 16). Clinical manifestations range
from mild pulmonary lesions to severe disseminated infection
involving many organs, most frequently the lungs, oropharyn-
geal mucosae, skin, lymph nodes, adrenal glands, and central
nervous system.
Many antigenic compounds expressed in the yeast forms of
P. brasiliensis are recognized by antibodies raised in human
patients (5–7, 14, 18, 23). The specificity of the serologic tests
depends on the antigen used. P. brasiliensis crude antigens have
components that are common with those of other fungi, which
can explain the cross-reactivity with the sera of patients with
other fungal diseases, such as histoplasmosis or Jorge Lobo’s
disease (4). Glycoprotein 43 (gp43), the major exoantigen se-
creted by P. brasiliensis, is a reliable antigen for immunodiag-
nostic assays (6, 15); however, the glycoepitopes of gp43 may
be common to different fungi and may explain the cross-reac-
tivity with heterologous sera, which is frequently abolished by
the deglycosylation of gp43 (26). Some patients may be sero-
logically negative for gp43 at the time of the diagnosis, whereas
others exhibit persistent levels of specific antibodies following
recovery from PCM (4). Therefore, a definitive diagnosis of
PCM requires visualization or isolation of the fungus from
infected tissue. Clinicians use specific antibody detection
mainly to evaluate the patient’s immune response to antifungal
therapy, since decreasing levels of specific anti-P. brasiliensis
gp43 antibodies have been documented in patients with good
clinical responses to antifungal therapy (4).
Besides gp43, other proteins, glycoproteins, and glycosphin-
golipids (GSLs) present in P. brasiliensis are antigenic (i.e.,
provoke an immune response) in humans (6, 12, 14, 18, 23).
GSLs are present in all eukaryotic cells and vary widely in their
glycan and ceramide structures, depending on the species, tis-
sue, and stage of differentiation/development. We showed
previously that glucosylceramide (GlcCer) is the only neutral
GSL in the yeast and the mycelium forms of P. brasiliensis but
that two glycosylinositolphosphorylceramide (GIPC) antigens
(acidic GSLs), termed Pb-1 and Pb-2, are present (11, 23, 24).
The sera of patients with PCM reacted strongly with Pb-1,
which comprises 90 to 95% of the acidic GSLs of the yeast
forms, whereas the sera of patients with histoplasmosis and
Jorge Lobo’s disease showed no cross-reactivity with Pb-1 (23).
The structure of Pb-1 was elucidated as Galf1-6(Man1-
3)Man1-2Ins-P-Cer (11). Pb-2 comprises the remaining 5 to
10% of the acidic GSLs of yeast forms. It differs from Pb-1 in
the absence of a terminal Galf residue and probably represents
the biosynthetic precursor of Pb-1.
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In order to identify new antigens potentially useful as mark-
ers of fungal infection, we evaluated the clearance of antibod-
ies directed to P. brasiliensis GSLs in serum samples of PCM
patients during antifungal treatment. Serum samples were also
tested to evaluate the immunoglobulin (Ig) classes and IgG
subclasses of host antibodies directed to the fungal GSLs.
MATERIALS AND METHODS
Serum samples. Serum samples were collected from 31 patients with chronic
PCM before and/or after the start of antifungal treatment. A total of 38 serum
samples were analyzed, with seven serum samples obtained from the same
patients at different stages of treatment. The diagnosis of PCM for the patients
enrolled in the study was confirmed by the observation of characteristic P.
brasiliensis fungal elements on histopathologic examination, direct KOH exam-
ination, and/or culture from clinical specimens. Serum samples were aliquoted
and frozen at 70°C for no longer than 2 years before they were tested.
The clearance of antibodies directed to P. brasiliensis GSLs in serum samples
of PCM patients was evaluated by testing samples collected (i) before treatment
(BT; n  10), (ii) during the first 4 months of treatment (T1-4; n  9), (iii) from
months 5 to 12 of treatment (T5-12; n  9), and (iv) after 3 years of successful
therapy with antifungal drugs (posttreatment [PT]; n  10).
Table 1 summarizes the clinical characteristics of the PCM patients enrolled in
the study. Forty-three percent of the study patients were from Sa˜o Paulo State,
20% were from Parana´, 26% were from Minas Gerais, and 11% were from other
states of Brazil (Paraı´ba, Bahia, Mato Grosso do Sul, and Rio Grande do Sul).
All PCM patients were successfully treated with sulfamethoxazole-trimethoprim
at doses ranging from 800/160 to 1,200/240 mg twice a day for at least 2 years
(19). In addition, 6 serum samples from patients with invasive candidiasis, 14
serum samples from patients with pulmonary aspergillosis, and 9 serum samples
from patients with the chronic form of Chagas’ disease were also analyzed.
Twelve serum samples from healthy volunteers (blood donors) were included as
controls.
All patients were informed and signed a consent form for this investigation.
The study protocol was approved by the Institutional Ethics Committee of
Universidade Federal de Sa˜o Paulo.
Culture of P. brasiliensis. P. brasiliensis B-339 (ATCC 200273) was provided by
Zoilo P. Camargo, Cellular Biology Discipline, Universidade Federal de Sa˜o
Paulo. The yeast and the mycelium forms were grown at 36°C and 23°C, respec-
tively, in PGY (peptone, 5 g/liter; glucose, 15 g/liter; yeast extract, 5 g/liter)
supplemented with thiamine (0.1 g/liter) and asparagine (1.4 g/liter) by using
2.5-liter Fernbach flasks in a shaker at 100 rpm. After 1 week, the yeast and the
mycelium forms were inactivated with 0.1% thimerosal, and fungi were collected
48 h later by filtration on Whatman no. 1 filter paper (20).
Extraction and purification of GSLs. GSLs were extracted by homogenizing
the yeast or the mycelium forms (30 g) in an Omni-mixer (Sorvall Inc., Wil-
mington, DE) three times with 200 ml isopropanol-hexane-water (55:20:25; the
upper phase was discarded) and twice with 200 ml chloroform-methanol (2:1) (all
solvent ratios are by volume) (21). The five extracts were pooled, dried on a
rotary evaporator, dialyzed against water, and lyophilized.
GSL preparations were separated by DEAE-Sephadex chromatography into
(i) neutral GSLs eluted with chloroform-methanol-water (30:60:8) and (ii) acidic
GSLs eluted with 0.2 M sodium acetate in methanol (12). Acidic GSLs were
dried in a rotary evaporator, resuspended in water, dialyzed against water for
72 h, and dried. The Pb-1 and Pb-2 GSLs were purified by high-performance
liquid chromatography on an Iatrobeads 8010 (Iatron Laboratories, Inc., Tokyo,
Japan) column with a gradient of isopropanol-hexane-water from 55:43:2 to
55:20:15 over 175 min with a flow rate of 1.0 ml/min. Fractions of 1 ml were
collected. The identity and purity of each fraction were assessed by analytical
high-performance thin-layer chromatography (HPTLC). Fractions 62 to 64 (cor-
responding to Pb-2) and fractions 67 to 74 (corresponding to Pb-1) were used for
all subsequent experiments. The monohexosylceramide present in the neutral
fraction was further purified from other contaminants by chromatography on
Silica Gel 60 by using a stepwise gradient of chloroform-methanol (98:2, 94:6,
92:8, 90:10, 70:30, 50:50). Glucosylceramide was the only GSL present in the
fraction eluted with chloroform-methanol (90:10). The purities of GlcCer, Pb-1,
and Pb-2 were determined by HPTLC on Silica Gel 60 plates (Merck, Darmstadt,
Germany) with the solvent chloroform-methanol-CaCl2 (0.02%; 60:40:9) and by
staining with 0.5% orcinol (Sigma Chemical Co., St. Louis, MO) in 3.0 M H2SO4
(the plate was sprayed and briefly heated to 120°C, and the glycolipids were
visualized as purple bands), 0.01% primulin (Aldrich Chemical Co., Milwaukee,
WI) in 80% aqueous acetone (the GSL bands were visualized under UV light
after the plate was sprayed), and the molybdenum blue spray reagent (Sigma
Chemical Co.) for the phospholipids.
ELISA for anti-GSL antibodies. Purified GSLs (25 l of a 4-g/ml solution in
ethanol) were added to 96-well plates (Microtest III flexible assay plates; Falcon,
Oxnard, CA) and dried at 37°C, and the wells were blocked with 0.01 M phos-
phate-buffered saline (PBS; pH 7.2) containing 5% bovine serum albumin (BSA)
and 10% skim milk for 3 h at 25°C. The plates were incubated sequentially with
(i) sera from patients or control subjects overnight at 4°C; (ii) anti-human IgG
(heavy and light chains) biotinylated antibody (Dako, Denmark) diluted 1:1,000
in BSA-PBS or biotinylated specific anti-human IgG ( chain), IgG1, IgG2,
IgG3, IgG4, IgM ( chain), IgA, and IgE (Southern Biotechnology, Inc., Bir-
mingham, AL) for 2 h at 25°C; and (iii) horseradish peroxidase-streptavidin
(Dako) (1:2,000) for 1 h at 25°C. Antibody levels were expressed as the mean
absorbance values (at 492 nm) for duplicate assays minus the absorbance value
for the blank (absorbance values for each serum dilution in plates without
adsorbed GSL).
The cutoff for each GSL was determined by using 12 serum samples from
healthy donors. The enzyme-linked immunosorbent assay (ELISA) was per-
formed on 96-well plates adsorbed with 100 ng of each GSL per well. Cutoff
values were calculated as the mean 	 3 standard deviations (2).
Antibody titers were determined as the last serum dilution with an absorbance
value higher than the cutoff value.
IgG avidity to Pb-1 antigen. The avidities of the anti-Pb-1 antibodies were
estimated by the method of Jenum et al. (9) from their capacities to remain
bound to the antigen in the presence of 6.0 M urea. Each serum sample was
analyzed in a fourfold dilution range (starting at 1:25) in two rows (rows A and
B) overnight at 4°C. After incubation, row A was washed three times with PBS
containing 6.0 M urea at 25°C to remove the low-avidity antibodies from their
binding sites. Row B (control) was washed with PBS only at 25°C. During each
washing step, the microtiter plate was shaken vigorously for 5 min. Subsequent
steps of the reaction were the same as those of the standard ELISA. The
secondary antibody used was anti-human  chain biotinylated antibody. For each
serum sample, avidity was calculated as (titer in row A/titer in row B) 
 100 and
the titer was calculated a 1/(dilution x 
 10n), where dilution x is the highest
dilution giving an absorbance value higher than the cutoff (0.22) and n is equal
to log 4 [(ODx 0.220)/(ODxODy)], where 4 is the dilution factor, ODx is the
absorbance (optical density) at dilution x, 0.220 is the cutoff OD, and ODy is the
absorbance at the next dilution after dilution x.
Statistical analysis. The values obtained for different PCM treatment
groups were compared by the Mann-Whitney test by using GraphPad Prism
software, version 3.0. Differences were considered significant if the P value
was 0.05.
RESULTS
Reactivities of sera from PCM patients with GSL antigens
of P. brasiliensis. The glucosylceramide, Pb-1, and Pb-2 anti-
TABLE 1. Sera of patients with PCM
Patient
group Age (yr)
Clinical form of PCM
(no. of patients)
No. of patients with the following
immunodiffusion test result at the
indicated titersa:
Negative
Positive
1:1–1:2 1:4–1:8 1:16
BT 39–53 Multifocal (9) 1 4 3 1
64 Unifocal (1) 1
T1-4 38–62 Multifocal (8) 1 5 2
50 Unifocal (1) 1
T5-12 39–61 Multifocal (8) 3 5
47 Unifocal (1) 1
PT 43–71 Multifocal (9) 6 3
61 Unifocal (1) 1
a Immunodiffusion was performed with the Paracoccidioides brasiliensis so-
matic antigen as described previously (5).
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gens were purified from the yeast forms of P. brasiliensis as
described in Materials and Methods. The chromatographic
profiles of the purified GSLs used for ELISA are shown in
Fig. 1A. Sera pooled from five PCM patients before treat-
ment were initially tested with serially diluted antigens, us-
ing a starting concentration of 200 ng/well. Only Pb-1 was
recognized by patient sera. Fifty percent of the maximal
reactivity was observed with approximately 25 ng Pb-1 per
well (Fig. 1B).
In order to evaluate the expression and clearance of anti-P.
brasiliensis GSL antibodies during PCM treatment, the sera
were analyzed by ELISA with the three GSLs, as described
above, at 100 ng/well. Antibody reactivity against Pb-1 (Fig.
2A) but not against Pb-2 (Fig. 2B) or glucosylceramide (Fig.
2C) was observed. The level of expression of the anti-Pb-1
antibody was significantly higher in the BT group or the T1-4
group than in the T5-12 or the PT group. Since the sera of the
PCM patients were reactive with Pb-1 [Galf1-6(Man1-
3)Man1-2Ins-Cer] but not with Pb-2 (Man1-3Man1-2Ins-
Cer), the Galf residue appears to be a key molecule for anti-
body recognition. Similarly, the sera of patients with Chagas’
FIG. 2. Reactivities of sera of patients with PCM and Chagas’ disease
with various GSLs. Samples (100 ng) of Pb-1 (A), Pb-2 (B), and GlcCer
(C) were adsorbed on 96-well plates and incubated with sera from PCM
patients (diluted 100 times) taken at various stages of treatment (BT, n
10; T1-4, n 9; T5-12, n 9; PT, n 10) or with sera from patients with
Chagas’ disease (CD; n 9), patients with invasive candidiasis (CAN; n
6), or patients with pulmonary aspergillosis (ASP; n 14). The amount of
Ig bound to each GSL was determined by using biotinylated anti-IgG
(heavy and light chains), as described in Materials and Methods. Serum
reactivity was analyzed by ELISA. Short horizontal lines, mean absor-
bance for each group; long horizontal lines, cutoff determined for sera
from healthy subjects (NS; n  12). Abs, absorbance.
FIG. 1. Purified GSLs from P. brasiliensis and their immunogenici-
ties. (A) HPTLC pattern of purified GSLs from P. brasiliensis obtained
by using the solvent chloroform-methanol-CaCl2 (0.02%) and staining
with orcinol-H2SO4. Lane 1, total P. brasiliensis GSLs; lane 2, purified
GlcCer; lane 3, purified Pb-2; lane 4, purified Pb-1. (B) Reactivities of
sera from PCM patients (n 5; diluted 100 times) with Pb-1 (squares),
Pb-2 (triangles), and GlcCer (circles) purified from P. brasiliensis by
ELISA before treatment. Various concentrations of GSLs were ad-
sorbed on 96-well plates, and the plates were blocked and incubated
overnight at 4°C with pooled patient sera (n  5). The amount of Ig
bound to each GSL was determined by using biotinylated anti-IgG
(heavy and light chains), as described in Materials and Methods. Abs,
absorbance.
152 BERTINI ET AL. CLIN. VACCINE IMMUNOL.
disease contained antibodies directed to Trypanosoma cruzi
GIPCs with a terminal Galf residue 1-3 linked to mannose (8,
27). However, the sera from patients with Chagas’ disease
showed no reactivity with the Pb-1 antigen (Fig. 2A). Also, as
shown in Fig. 2A, only 1 of 6 serum samples from patients with
invasive candidiasis (n  6) and 2 of 14 serum samples from
patients with pulmonary aspergillosis presented cross-reactiv-
ity with Pb-1 by ELISA.
Figure 3 presents the anti-Pb-1 antibody titers, determined
by ELISA, in four groups of patients at different stages of
antifungal treatment. Although the samples are not matched, it
is possible to note that the highest anti-Pb-1 titers were ob-
served during the first 4 months of treatment (T1-4 group) and
that the titers were significantly higher (P  0.05) than the
titers observed in the BT, T5-12, and PT groups. It is worth
mentioning that all patients responded positively to the treat-
ment. The mean value of the anti-Pb-1 antibody titer in pa-
tients during the first 4 months of treatment (T1-4 group) was
almost four times higher than the mean value for the BT
group. On the other hand, after 5 months of treatment, as the
clinical symptoms declined, the anti-Pb-1 antibody titers also
declined to almost 1/10.
In order to determine the titers of the anti-Pb-1 antibodies
and isotype expression during PCM treatment, the sera of the
four patient groups were assayed by using specific anti-human
IgG, IgM, IgA, and IgE antibodies. Anti-Pb-1 IgM antibodies
were detected at levels above the cutoff value in 60% of the BT
group and 20% of the T1-4 group (Fig. 4A). IgM is clearly the
initial response to the Pb-1 antigen. The IgM titer decreased
during the course of treatment, indicating IgM-IgG switching;
no anti-Pb-1 IgM was detected in the T5-12 or PT group. On
the other hand, IgG was the main class directed to the Pb-1
antigen in the four PCM groups; i.e., these antibodies were
detected at levels above the cutoff vlaue in 100% of the BT and
T1-4 groups and 90% of the T5-12 and PT groups (Fig. 4B).
The level of expression of anti-Pb-1 IgA was found to be
above the cutoff value in 50% of the BT and T1-4 groups
(Fig. 4C). No statistically significant expression of anti-Pb-1
IgE was detected in the four PCM groups, although three
patients in the T1-4 group, as well as two patients of the
FIG. 3. Pb-1 antibody titers in PCM patient serum. Purified Pb-1
antigen (100 ng/well) was adsorbed on a 96-well plate and incubated
with serially diluted sera from the PCM patient groups, as defined in
the legend to Fig. 2. The amount of bound antibody was determined by
ELISA with biotinylated mouse anti-human IgG (heavy and light
chains). The titer was determined as the last serum dilution with an
absorbance value higher than 0.1.
FIG. 4. Expression of Ig directed to Pb-1 antigen in PCM patient sera. Purified Pb-1 (100 ng/well) was adsorbed on a 96-well plate and
incubated with sera from the PCM patient groups, as defined in the legend to Fig. 2. The amount of bound antibody was determined by ELISA
with biotinylated mouse anti-human Ig, as described in Materials and Methods. (A) IgM ( chain); (B) IgG ( chain); (C) IgA; (D) IgE. The short
and the long horizontal lines are as defined in the legend to Fig. 2. Abs, absorbance.
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posttreatment group, presented absorbance values above
the cutoff (Fig. 4D).
After the determination that IgG is the main class of anti-
Pb-1 antibody, we investigated the reactive subclasses. Approx-
imately 80% of the BT group and 100% of the T1-4 group
expressed anti-Pb-1 IgG1 at levels above the cutoff value (Fig.
5A). The median absorbance at 492 nm was significantly higher
in the T1-4 group than in the BT group (0.806 and 0.327,
respectively; P  0.0133). Lower levels of anti-Pb-1 IgG1, but
levels above the cutoff, were detected in 50% of the T5-12
group, and weak reactivity with IgG1 was detected in 50% of
the PT group. No statistically significant expression of IgG2,
IgG3, or IgG4 directed to the Pb-1 antigen was detected in any
of the groups of PCM patients (Fig. 5B to D). It is worth
mentioning that one serum sample from the BT group and two
serum samples from the T1-4 group showed titers of anti-Pb-1
IgG2 antigen above the cutoff, which probably compensated
for the low levels of anti-Pb-1 IgG1 and IgM detected in these
sera (Fig. 5B).
Sera from PCM patients were subjected to ELISA to test the
capacity of anti-Pb-1 IgG antibodies to remain bound to the
Pb-1 antigen (“avidity”) after the 96-well plates were washed
with PBS containing 6.0 M urea, as described in Materials and
Methods. The avidities of the antibodies to Pb-1 expressed in
the sera of patients with the chronic form of PCM varied from
12 to 74% (mean, 50%) in the BT, T1-4, and T5-12 groups
(Fig. 6). However, it should be noted that no statistically sig-
nificant differences in the avidities of the anti-Pb-1 antibodies
were observed among the four groups.
DISCUSSION
Among the GSLs expressed in P. brasiliensis, only Pb-1, a
GIPC with a terminal Galf residue, is immunogenic for hu-
mans. Since Pb-2, the putative biosynthetic precursor of Pb-1,
does not react with the sera of PCM patients and does not have
a terminal Galf residue, the present data indicate that Galf is
the essential residue that elicits the production of PCM serum
FIG. 5. Expression of IgG subclass directed to Pb-1 antigen in PCM patient sera. Purified Pb-1 (100 ng/well) was adsorbed on a 96-well plate
and incubated with sera from the PCM patient groups, as defined in the legend to Fig. 2. The amount of bound antibody was determined by ELISA
with biotinylated mouse anti-human Ig, as described in Materials and Methods. (A) IgG1; (B) IgG2; (C) IgG3; (D) IgG4. The short and the long
horizontal lines are as defined in the legend to Fig. 2. Abs, absorbance.
FIG. 6. Avidity of anti-Pb-1 IgG antibody present in PCM patient
sera. Sera from patients with chronic PCM were serially diluted and
incubated in 96-well plates preadsorbed with 100 ng Pb-1. The avidities
of the anti-Pb-1 antibodies, defined as the capacity to remain bound to
the Pb-1 antigen in the presence of 6.0 M urea in PBS, were deter-
mined by ELISA. Antibody binding was determined with biotinylated
anti-human IgG ( chain) as the secondary antibody, as described in
Materials and Methods. Bars, mean absorbance value for each group.
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antibodies. The Galf residue has also been shown to be immu-
nogenic in other infectious diseases, such as Chagas’ disease (8,
27), in which patients produce antibodies directed to the ter-
minal Galf of the GIPCs of T. cruzi. However, the sera of
patients with Chagas’ disease do not cross-react with Pb-1,
indicating that antibodies directed to the residues of beta-Galf
expressed in patients with Chagas’ disease and PCM present
distinct specificities. Of all the heterologous serum samples
tested (6 from patients with invasive candidiasis and 14 from
patients with pulmonary aspergillosis), only 1 from a patient
with candidiasis and 2 from patients with aspergillosis had
positive reactivities. Toledo et al. (23) reported that sera from
patients with histoplasmosis or Jorge Lobo’s disease do not
cross-react with the Pb-1 antigen. Therefore, Pb-1 appears to
be a useful antigen for the immunodiagnosis of PCM. The
ELISA with Pb-1 gave a sensitivity of 100% and a specificity of
96.1%. On the other hand, a lower specificity (about 90%) was
observed when the P. brasiliensis somatic antigen was used in
the immunodifusion test. For the ELISA with the Pb-1 antigen,
the positive and the negative predictive values were 90% and
100%, respectively. Considering that the distributions of the
antibody titers at the baseline and at the end of therapy were
statistically different, there is also potential for the use of the
ELISA not only for diagnosis but also as a surrogate marker of
a good clinical response.
No differences in reactivities to GlcCer purified from P.
brasiliensis between the sera from healthy donors and the sera
from the PCM patients were detectable by ELISA. However, it
should be noted that the cutoff for GlcCer was slightly higher
than those for Pb-1 and Pb-2, suggesting that sera from healthy
subjects may contain trace amounts of anti-GlcCer antibodies
or antibodies that cross-react with fungal GlcCer. Our results
are inconsistent with those of Rodrigues et al. (17), who de-
tected antibodies directed to GlcCer of Cryptococcus neofor-
mans, which is structurally identical to the GlcCer purified
from P. brasiliensis, in the sera from patients with PCM or
cryptococcal infection (24, 25). Even using a high concentra-
tion of GlcCer, i.e., 10 g/well, we were not able to detect
anti-GlcCer antibodies in the sera of patients with PCM by
ELISA (data not shown). It was observed that the sera of
patients with PCM present antibodies directed to Pb-1 but do
not present antibodies directed to GlcCer.
P. brasiliensis GSL antigens, specifically, those that contain
the Galf residue, elicit a primary IgM response and subse-
quently an IgG1 response. As patients begin antifungal treat-
ment and develop a better immune response against P. brasil-
iensis, their titers of anti-Pb-1 IgG1 increase. After 5 months of
treatment, as the clinical symptoms decline, the anti-Pb-1 an-
tibody titers also decline. Similar patterns of immune response
to gp43, the major exoantigen of P. brasiliensis, and to crude P.
brasiliensis extract were observed in the sera of patients with
chronic PCM (1, 10). Also, 3 of 10 patients in the T1-4 group
showed values of IgE above the cutoff (Fig. 4D). Interestingly,
Biselli et al. (2) described that IgE antibodies directed to gp43
are produced at high levels by most patients with the acute
form of PCM, whereas anti-gp43 IgE antibody titers above the
cutoff were detected in only 27% of patients with the chronic
form of PCM.
The present study shows that antibodies directed to P. bra-
siliensis GSLs in patients with chronic PCM are of the IgG1
isotype and display a 50% avidity to the Pb-1 antigen. IgG1
may have an important role in fungal clearance, since Pb-1 is
highly expressed on the yeast surface (22). P. brasiliensis coated
with IgG1 could bind specifically to Fc receptors on the sur-
faces of phagocytes (monocytes and neutrophils), which re-
move pathogens and their degradation products from extracel-
lular spaces. Furthermore, natural killer (NK) T cells have the
ability to destroy antibody-coated target cells through the an-
tibody-dependent cell-mediated cytotoxicity (ADCC) trig-
gered by the interaction between IgG1 on the yeast surface and
the FcRIII (CD16) expressed on NK cells (13). This receptor
recognizes IgG1 and IgG3 antibodies and is involved in the
release of perforin and granzymes from cytoplasmic granules.
ADCC is well documented as a mechanism for antigen-specific
attack by an effector cell; however, such an attack by an effec-
tor cell that itself has a role in defense against fungal infection
has not been fully established.
These results provide an important advance in our knowl-
edge of the immune responses in patients with PCM, particu-
larly those against GSL antigens. GIPCs with terminal galacto-
furanose residues have clear potential application as elicitors
of the host immune response.
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